Close Menu

NEW YORK – Some patients with advanced cancers harboring mutations in the RAS-RAF-MEK pathway — including those with difficult-to-target KRAS mutations — had durable responses while avoiding dose-limiting toxicities on Verastem Oncology's investigational VS-6766, the results of a recently published study showed.

These data give Verastem more confidence in its plan to advance VS-6766, a MEK and pan-RAF inhibitor, into two registration-enabling studies in lung and ovarian cancer by the end of the year.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.